Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
Cardiovascular Disease
SEQUOIA-HCM Trial: Aficamten in HCM
SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
IRONMAN Trial: IV Iron in HF
IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
Bridge-TIMI 73a Trial: Olezarsen for Hypertriglyceridemia
Bridge–TIMI 73a Trial Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk A randomized, placebo-controlled, double-blind trial Objective:To assess the efficacy and safety of olezarsen for lowering triglyceride levels in patients with moderate hypertriglyceridemia plus elevated cardiovascular risk and in … Read More
FCS BALANCE: Olezarsen in Familial Chylomicronemia Syndrome
FCS BALANCE Trial Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (FCS) A phase 3, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of olezarsen (given once every 4 weeks) in reducing fasting triglyceride level in patients with familial chylomicronemia … Read More
DEA-HF Trial: Diuretics Regimen in CHF
The infographic details findings from the DEA-HF study, which was designed to evaluate the efficacy and safety of three different diuretic treatment regimens in patients with ambulatory congested heart failure (CHF). The study was conducted in a prospective, randomized, open-label, … Read More
The Therapeutic Potential of Apolipoprotein A1 Infusion in Cardiovascular Disease Management
Introduction Apolipoprotein A1 (ApoA1), the primary protein component of High-Density Lipoprotein (HDL), plays a crucial role in reverse cholesterol transport, a vital process for cardiovascular health. Recent advancements in cardiovascular therapeutics have seen innovative approaches such as ApoA1 infusion, aiming … Read More
ULTIMATE-DAPT: Ticagrelor Monotherapy after ACS
“ULTIMATE-DAPT” trial summary. It presents the results of a clinical trial comparing the use of ticagrelor alone versus the combination of ticagrelor and aspirin following percutaneous coronary intervention (PCI) in patients with Acute Coronary Syndrome (ACS) from month 1 to … Read More
DanGer Shock Trial: Impella in Cardiogenic Shock
“DanGer Shock” study, which is an international, open-label, randomized trial examining the impact of a Microaxial Flow Pump (Impella CP) plus standard care versus standard care alone in infarct-related cardiogenic shock. Objective: To compare the safety and efficacy of Impella … Read More